Relationships between biomarkers in aging and dementia

Neurology

Volumn 73, Issue 15, 2009, Pages 1193-1199

  Jagust, William J ^a   Landau, S M ^a   Shaw, L M ^b   Trojanowski, J Q ^b   Koeppe, R A ^c   Reiman, E M ^d   Foster, N L ^e   Petersen, R C ^f   Weiner, M W ^g   Price, J C ^h   Mathis, C A ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Center for Neurodegenerative Disease Research   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d BANNER ALZHEIMER S INSTITUTE   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f Mayo Clinic   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B 11 C; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGRESSION ANALYSIS;

AGED; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS; THIAZOLES;

EID: 70350152831     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181bc010c     Document Type: Article

References (31)

1. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289: 2094-2103.
2. Ronald and Nancy Reagan Research Institute of the Alzheimer?s Association and the National Institute on Aging Working Group. Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer?s disease." Neurobiol Aging 1998;19:109-116.
3. Hansson O, Zetterberg H, Blennow K. Evaluation of plasma A/340 and A/342 as predictors of conversion to Alzheimer?s disease in patients with mild cognitive impairment. Neurobiol Aging Epub 2008 Oct 25.
4. Blennow K, Vanmechelen E, Hampel H. CSF total tau, A/342 and phosphorylated tau protein as biomarkers for Alzheimer?s disease. Mol Neurobiol 2001;24:87-97.
5. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer?s disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-319.
6. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001; 286:2120-2127.
7. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007;69:871-877.
8. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer?s disease. Brain 2007;130:2616-2635.
9. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
10. Rabinovici GD, Furst AJ, O?Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205-1212.
11. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer?s disease. Brain 2007;130: 2837-2844.
12. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A/342 in humans. Ann Neurol 2006;59:512-519.
13. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007;64:343-349.
14. Fellgiebel A, Siessmeier T, Scheurich A, et al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004;56:279-283.
15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer?s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer?s Disease. Neurology 1984;34: 939-944.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
17. Wechsler D. Wechsler Memory Scale-Revised. San Antonio: The Psychological Corporation; 1987.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer?s disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403-413.
19. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.
20. Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46:1959-1972.
21. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132(pt 5): 1310-1323.
22. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-1465.
23. Koivunen J, Pirttila T, Kemppainen N, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378-383.
24. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometab-olism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501-508.
25. Ceravolo R, Borghetti D, Kiferle L, et al. CSF phosphory-lated Tau protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer?s disease. Brain Res Bull 2008;76:80-84.
26. Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apoli-poprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008;63:609-618.
27. Haense C, Buerger K, Kalbe E, et al. CSF total and phos-phorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer?s disease. Eur J Neurol 2008;15:1155-1162.
28. Sunderland T, Wolozin B, Galasko D, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry 1999;46:750-755.
29. Zetterberg H, Pedersen M, Lind K, et al. Intra-individual stability of CSF biomarkers for Alzheimer?s disease over two years. J Alzheimers Dis 2007;12:255-260. (Pubitemid 350179256)
30. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer?s disease. Brain 2006;129:2856-2866.
31. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer?s disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.